Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/147217
Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration?>?400?ng/ml), which represents an accepted prognostic cut-off and a predictor of response to ramucirumab. Those AFP-high tumours (18% of resected cases) were characterised by significantly lower AFP promoter methylation (p?
Matèries
Matèries (anglès)
Citació
Citació
MONTAL, Robert, ANDREU OLLER, Carmen, BASSAGANYAS, Laia, ESTEBAN FABRÓ, Roger, MORAN, Sebastian, MONTIRONI, Carla, MOEINI, Agrin, PINYOL, Roser, PEIX, Judit, CABELLOS, Laia, VILLANUEVA, Augusto, SIA, Daniela, MAZZAFERRO, Vincenzo, ESTELLER, Manel, LLOVET I BAYER, Josep maria. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. _British Journal of Cancer_. 2019. Vol. 121, núm. 340–343. [consulta: 23 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/147217]